Remove DNA Remove Genome Remove Immune Response Remove Protein
article thumbnail

Rome Therapeutics raises $77m for junk DNA-targeting drugs

pharmaphorum

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – for hidden treasure. Most drug discovery programmes target the roughly 2% of the human genome which encodes for protein.

DNA 52
article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs). In November 2023, Hookipa Pharma Inc.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Beyond the Pill: The Rise of Biologics and the Evolution of Pharmaceutical Therapies

Cloudbyz

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology.

Gene 83
article thumbnail

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Delveinsight

The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa). Interferons are naturally occurring proteins in the body; recombinant IFNa is the protein-based drug that works to mobilize the body’s natural immune system to fight disease.

article thumbnail

Delivering on the promise of gene editing

Drug Discovery World

These platforms all induce double strand cuts in the chromosomal DNA that can be sealed by the cell, leading to a specific gene disruption, or resulting in a new target site for inserting DNA segments. Reduce/eliminate chromosomal disruptions caused by double-strand DNA breaks. In one example, Choi et al.

article thumbnail

The path to improved safety of gene-based products

Drug Discovery World

Kerstin Pohl , Senior Global Marketing Manager, Gene Therapy & Nucleic Acid at SCIEX, looks at the application of liquid chromatography-mass spectrometry for analysing host cell proteins. Host cell proteins (HCPs) – proteins derived from the host cells used for viral production—are one class of process-related impurities.

article thumbnail

Who are the AACR Scientific Achievement Award winners?

Drug Discovery World

He is being recognised for his inspiring contributions to genomic studies dedicated to analysing therapeutic response rates in multi-ethnic paediatric acute lymphoblastic leukaemia patient populations, which have resulted in the identification of a large number of genomic loci responsible for driving therapeutic response variability.